Epidemiological studies have shown that humans with altered circadian rhythms have higher cancer incidence, with breast cancer being one of the most cited examples. To uncover how circadian disruptions may be correlated with breast cancer and its development, prior studies have assessed the expression of BMAL1 and PER2 core clock genes via RT-qPCR and western blot analyses. These and our own low-resolution data show that BMAL1 and PER2 expression are suppressed and arrhythmic. We hypothesized that oscillations persist in breast cancer cells, but due to limitations of protocols utilized, cannot be observed. This is especially true where dynamic changes may be subtle. In the present work, we generated luciferase reporter cell lines representing high-and low-grade breast cancers to assess circadian rhythms. We tracked signals for BMAL1 and PER2 to determine whether and to what extent oscillations exist and provide initial correlations of circadian rhythm alterations with breast cancer aggression. In contrast to previous studies, where the clock was deemed to be "broken" in breast cancer, our luminometry data reveal that circadian oscillations of BMAL1 and PER2 do in fact exist in the low-grade, luminal A cell line, MCF7 but are not apparent in high-grade, basal MDA-MB-231 cells.
Introduction
Circadian rhythms are biological changes that follow a daily cycle, responding primarily to light and darkness in an organism's environment. Their disruption has been associated with increased risk of several cancers, including breast. 1 Circadian rhythms are regulated by a molecular circadian clock comprising CLOCK, BMAL, PER, and CRY proteins.
Oscillations of these and ancillary circadian genes have been found to be arrhythmic/absent in several disease models and tissues, including peripheral blood mononuclear cells from chronic myeloid leukemia, 2 colorectal liver metastases, 3 and prostate 4 and breast cancer cell lines. [5] [6] [7] [8] In most of these cases, RT-qPCR, western blots, and immunohistochemistry were used to evaluate circadian changes. These assays result in less-detailed oscillation assessments because sampling frequency is typically 4-6 h and the experiment covers ~48 h; more time-points and collection over a longer duration are difficult to achieve. Similar studies revealed that core clock gene transcripts are present, but do not oscillate in breast cancer cell lines. [6] [7] [8] [9] [10] As examples, in work using MCF7 and MDA-MB-231 (among other breast cancer) cells, RT-qPCR and DNA/miRNA microarray data show that core circadian genes BMAL1 and PER2 lack rhythmic oscillations, although some clock controlled genes (CCGs) and miRNAs are rhythmic. 6, 8 Another study in MCF7 cells indicated that upon synchronization, some core clock genes 
Synchronization of Cells by Serum Shock
Cells were seeded in 35 mm culture dishes at 2
x 10 5 cells/mL and incubated for 1-3 days. Confluent cells were washed with PBS (Gibco) and starved in DMEM media supplemented only with 1% L-glutamine for 12 h. Cells were then serum shocked using DMEM containing 50% FBS and 1% L-glutamine for 2 h.
RNA Extraction and cDNA Synthesis
Following synchronization, cells were washed with PBS and returned to starvation conditions. Cells were harvested with the first time point (T=0) taken prior to serum shock, and every 4 h thereafter for 48 h. Total RNA was extracted via TRIzol Reagent (Gibco) according to manufacturer's instructions (detailed protocols in Supporting Information).
Quantitative Real-Time PCR (RT-qPCR)
RT-qPCR was performed in 96-well plates. The 
Lentiviral Transductions
Plasmids were generated and stably transfected as previously described. 16 Immunoblots were imaged using an enhanced chemiluminescence system (ECL; ThermoFisher) and a G:Box iChemi XT imaging system (GeneSys).
Band intensities were analyzed via ImageJ.
Results and Discussion
To confirm prior studies, 6,7,10 we obtained RT-qPCR data tracking BMAL1 and PER2 in MCF7
and MDA-MB-231 cells. While both transcripts were present and detectable (Fig. 1) , oscillations were not rhythmic in the circadian range (p>0.05 using Metacycle). To evaluate circadian rhythms in a more detailed manner to reveal subtle changes, we elected to employ luciferase reporters. This method has been used to provide high resolution oscillations in a variety of models, 1, 11 but not in breast cancer.
To test our hypothesis that RT-qPCR assessments lack sufficient sensitivity to determine the presence or absence of circadian rhythms, we separately stably transfected BMAL1:luc and PER2:luc into MCF7 cells ( Fig. S1A and B) .
Subsequent luminometry experiments revealed that circadian oscillations of both BMAL1:luc and PER2:luc persisted with a typical antiphase relationship (Fig. 2 and S2) . The trend in the raw bioluminescence time-series was negatively sloped and curving, and therefore appeared to be quadratic or exponential. Removal of a quadratic ( Fig. 2A and   2B ) or exponential (Fig. S3) To test our hypothesis that with increasing breast tumor grade/aggressiveness, cellular circadian rhythms are increasingly disrupted, we stably transfected BMAL1:luc and PER2:luc separately into triple negative/basal MDA-MB-231 cells ( Fig. S1C and S1D). The luminometry data from these highly aggressive cells revealed no visually detectable oscillations ( Fig. 3, Fig. S4 ), even after removal of either a quadratic ( Fig. 3) or exponential (Fig. S5) trend. Very few statistically significant oscillations were observed (FFT-based test for rhythmicity yielded p<0.05 for only 1 of 12 BMAL1:luc and 3 of 12 PER2:luc recordings). 17 In addition to expressing these receptors. 20 It has also been shown that E2 treatment can enhance expression of BMAL1, CLOCK, PER1, and PER2. 9, 21, 22 We hypothesize that the presence of the ER-E2 pathway may contribute to the circadian oscillations present in MCF7 cells.
Future studies will examine other ER-positive breast cancer cell lines (i.e. ZR-75-1) to evaluate whether results obtained here remain consistent.
Another difference between MCF7 and MDA-MB-231 cells occurs in terms of epidermal growth factor receptor (EGFR) status. 23 MDA-MB-231 cells express EGFR to a greater degree than do MCF7 cells. Following activation via EGF, the EGFR cascade's downstream pathways, including Ras/MAPK and PI3K/mTOR, 24 have been shown to disrupt circadian rhythms via period alteration or clock gene suppression. 25, 26 This may be a cause of the arrhythmic oscillations observed in MDA-MB-231 cells. In the future, the role of EGFR in the circadian network should be further assessed.
Based on the data obtained, we conclude that RT-qPCR assessments are not sufficient to track low amplitude, subtle circadian oscillations in cancer cells. Additionally, we show that the clock is not arrhythmic (or "broken") in all breast cancers, as had previously been posited. Furthermore, via assessment of MDA-MB-231 cells, we provide initial evidence that 
